within Pharmacolibrary.Drugs.ATC.L;

model L04AG03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.25e-06,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0057,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0040999999999999995,
    k12             = 0.305,
    k21             = 0.305
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L04AG03</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Natalizumab is a humanized monoclonal antibody that selectively binds to the α4-subunit of integrins on the surface of leukocytes and inhibits their adhesion to endothelial cells, thereby preventing migration of immune cells into the brain and spinal cord. It is primarily approved for the treatment of relapsing forms of multiple sclerosis and is also used for Crohn's disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with relapsing-remitting multiple sclerosis, healthy volunteers; both male and female. Standard dosing regimen.</p><h4>References</h4><ol><li><p>Gelissen, LMY, Loveless, S, Toorop, AA, Howlett, J, Loeff, FC, Rispens, T, Killestein, J, Tallantyre, EC, &amp; van Kempen, ZLE (2024). Subcutaneous administration of natalizumab can lead to lower drug concentrations compared to intravenous administration. <i>Multiple sclerosis and related disorders</i> 90 105796–None. DOI:<a href=&quot;https://doi.org/10.1016/j.msard.2024.105796&quot;>10.1016/j.msard.2024.105796</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39096666/&quot;>https://pubmed.ncbi.nlm.nih.gov/39096666</a></p></li><li><p>Li, H, Shi, FH, Huang, SY, Zhang, SG, &amp; Chen, ML (2018). A Review on Clinical Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Natalizumab: A Humanized Anti-α4 Integrin Monoclonal Antibody. <i>Current drug metabolism</i> 19(14) 1213–1223. DOI:<a href=&quot;https://doi.org/10.2174/1389200219666180427165841&quot;>10.2174/1389200219666180427165841</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29708072/&quot;>https://pubmed.ncbi.nlm.nih.gov/29708072</a></p></li><li><p>Saida, T, Kira, JI, Kishida, S, Yamamura, T, Sudo, Y, Ogiwara, K, Tibung, JT, Lucas, N, &amp; Subramanyam, M (2017). Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study. <i>Multiple sclerosis and related disorders</i> 11 25–31. DOI:<a href=&quot;https://doi.org/10.1016/j.msard.2016.11.002&quot;>10.1016/j.msard.2016.11.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28104251/&quot;>https://pubmed.ncbi.nlm.nih.gov/28104251</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L04AG03;
